human adenoviru ahu vector robust vaccine platform howe present naturallyacquir neutral antibody may reduce vector efficacy potent readministr studi value immune response protect follow vaccine replicationincompet portion pay alter use avian influenza hn disease model value basic mouse differ dose express optic ahanoi hemagglutinin antigen path compare adhuha control rapidly genre antibody signifies tier day stronger cellular detect admins day challenge demons improv survive lower virus load value longterm month postvaccin show better importantly oppose significantly neutral pool individual overall navbar capable media swift strong offer promise 